Cargando…

Proteomic approach for understanding milder neurotoxicity of Carfilzomib against Bortezomib

The proteasomal system is responsible for the turnover of damaged proteins. Because of its important functions in oncogenesis, inhibiting the proteasomal system is a promising therapeutic approach for cancer treatment. Bortezomib (BTZ) is the first proteasome inhibitor approved by FDA for clinical a...

Descripción completa

Detalles Bibliográficos
Autores principales: Karademir, Betul, Sari, Gulce, Jannuzzi, Ayse Tarbin, Musunuri, Sravani, Wicher, Grzegorz, Grune, Tilman, Mi, Jia, Hacioglu-Bay, Husniye, Forsberg-Nilsson, Karin, Bergquist, Jonas, Jung, Tobias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6218500/
https://www.ncbi.nlm.nih.gov/pubmed/30397214
http://dx.doi.org/10.1038/s41598-018-34507-3
_version_ 1783368464219504640
author Karademir, Betul
Sari, Gulce
Jannuzzi, Ayse Tarbin
Musunuri, Sravani
Wicher, Grzegorz
Grune, Tilman
Mi, Jia
Hacioglu-Bay, Husniye
Forsberg-Nilsson, Karin
Bergquist, Jonas
Jung, Tobias
author_facet Karademir, Betul
Sari, Gulce
Jannuzzi, Ayse Tarbin
Musunuri, Sravani
Wicher, Grzegorz
Grune, Tilman
Mi, Jia
Hacioglu-Bay, Husniye
Forsberg-Nilsson, Karin
Bergquist, Jonas
Jung, Tobias
author_sort Karademir, Betul
collection PubMed
description The proteasomal system is responsible for the turnover of damaged proteins. Because of its important functions in oncogenesis, inhibiting the proteasomal system is a promising therapeutic approach for cancer treatment. Bortezomib (BTZ) is the first proteasome inhibitor approved by FDA for clinical applications. However neuropathic side effects are dose limiting for BTZ as many other chemotherapeutic agents. Therefore second-generation proteasome inhibitors have been developed including carfilzomib (CFZ). Aim of the present work was investigating the mechanisms of peripheral neuropathy triggered by the proteasome inhibitor BTZ and comparing the pathways affected by BTZ and CFZ, respectively. Neural stem cells, isolated from the cortex of E14 mouse embryos, were treated with BTZ and CFZ and mass spectrometry was used to compare the global protein pool of treated cells. BTZ was shown to cause more severe cytoskeletal damage, which is crucial in neural cell integrity. Excessive protein carbonylation and actin filament destabilization were also detected following BTZ treatment that was lower following CFZ treatment. Our data on cytoskeletal proteins, chaperone system, and protein oxidation may explain the milder neurotoxic effects of CFZ in clinical applications.
format Online
Article
Text
id pubmed-6218500
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-62185002018-11-07 Proteomic approach for understanding milder neurotoxicity of Carfilzomib against Bortezomib Karademir, Betul Sari, Gulce Jannuzzi, Ayse Tarbin Musunuri, Sravani Wicher, Grzegorz Grune, Tilman Mi, Jia Hacioglu-Bay, Husniye Forsberg-Nilsson, Karin Bergquist, Jonas Jung, Tobias Sci Rep Article The proteasomal system is responsible for the turnover of damaged proteins. Because of its important functions in oncogenesis, inhibiting the proteasomal system is a promising therapeutic approach for cancer treatment. Bortezomib (BTZ) is the first proteasome inhibitor approved by FDA for clinical applications. However neuropathic side effects are dose limiting for BTZ as many other chemotherapeutic agents. Therefore second-generation proteasome inhibitors have been developed including carfilzomib (CFZ). Aim of the present work was investigating the mechanisms of peripheral neuropathy triggered by the proteasome inhibitor BTZ and comparing the pathways affected by BTZ and CFZ, respectively. Neural stem cells, isolated from the cortex of E14 mouse embryos, were treated with BTZ and CFZ and mass spectrometry was used to compare the global protein pool of treated cells. BTZ was shown to cause more severe cytoskeletal damage, which is crucial in neural cell integrity. Excessive protein carbonylation and actin filament destabilization were also detected following BTZ treatment that was lower following CFZ treatment. Our data on cytoskeletal proteins, chaperone system, and protein oxidation may explain the milder neurotoxic effects of CFZ in clinical applications. Nature Publishing Group UK 2018-11-05 /pmc/articles/PMC6218500/ /pubmed/30397214 http://dx.doi.org/10.1038/s41598-018-34507-3 Text en © The Author(s) 2018 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Karademir, Betul
Sari, Gulce
Jannuzzi, Ayse Tarbin
Musunuri, Sravani
Wicher, Grzegorz
Grune, Tilman
Mi, Jia
Hacioglu-Bay, Husniye
Forsberg-Nilsson, Karin
Bergquist, Jonas
Jung, Tobias
Proteomic approach for understanding milder neurotoxicity of Carfilzomib against Bortezomib
title Proteomic approach for understanding milder neurotoxicity of Carfilzomib against Bortezomib
title_full Proteomic approach for understanding milder neurotoxicity of Carfilzomib against Bortezomib
title_fullStr Proteomic approach for understanding milder neurotoxicity of Carfilzomib against Bortezomib
title_full_unstemmed Proteomic approach for understanding milder neurotoxicity of Carfilzomib against Bortezomib
title_short Proteomic approach for understanding milder neurotoxicity of Carfilzomib against Bortezomib
title_sort proteomic approach for understanding milder neurotoxicity of carfilzomib against bortezomib
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6218500/
https://www.ncbi.nlm.nih.gov/pubmed/30397214
http://dx.doi.org/10.1038/s41598-018-34507-3
work_keys_str_mv AT karademirbetul proteomicapproachforunderstandingmilderneurotoxicityofcarfilzomibagainstbortezomib
AT sarigulce proteomicapproachforunderstandingmilderneurotoxicityofcarfilzomibagainstbortezomib
AT jannuzziaysetarbin proteomicapproachforunderstandingmilderneurotoxicityofcarfilzomibagainstbortezomib
AT musunurisravani proteomicapproachforunderstandingmilderneurotoxicityofcarfilzomibagainstbortezomib
AT wichergrzegorz proteomicapproachforunderstandingmilderneurotoxicityofcarfilzomibagainstbortezomib
AT grunetilman proteomicapproachforunderstandingmilderneurotoxicityofcarfilzomibagainstbortezomib
AT mijia proteomicapproachforunderstandingmilderneurotoxicityofcarfilzomibagainstbortezomib
AT hacioglubayhusniye proteomicapproachforunderstandingmilderneurotoxicityofcarfilzomibagainstbortezomib
AT forsbergnilssonkarin proteomicapproachforunderstandingmilderneurotoxicityofcarfilzomibagainstbortezomib
AT bergquistjonas proteomicapproachforunderstandingmilderneurotoxicityofcarfilzomibagainstbortezomib
AT jungtobias proteomicapproachforunderstandingmilderneurotoxicityofcarfilzomibagainstbortezomib